Alto Neuroscience (ANRO) Expected to Announce Quarterly Earnings on Tuesday

Alto Neuroscience (NYSE:ANRO - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.59) per share for the quarter.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.09. On average, analysts expect Alto Neuroscience to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Alto Neuroscience Price Performance

NYSE:ANRO opened at $2.33 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. The stock's 50-day simple moving average is $2.55 and its 200 day simple moving average is $3.68. The company has a market cap of $62.94 million, a P/E ratio of -0.91 and a beta of 1.87. Alto Neuroscience has a 52-week low of $1.60 and a 52-week high of $17.55.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ANRO shares. William Blair restated an "outperform" rating on shares of Alto Neuroscience in a research note on Friday, March 21st. HC Wainwright began coverage on Alto Neuroscience in a research note on Monday, April 7th. They issued a "buy" rating and a $10.00 price objective for the company. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Alto Neuroscience currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.40.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.